191 related articles for article (PubMed ID: 19078632)
21. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial.
Kirschner J; Schessl J; Schara U; Reitter B; Stettner GM; Hobbiebrunken E; Wilichowski E; Bernert G; Weiss S; Stehling F; Wiegand G; Müller-Felber W; Thiele S; Grieben U; von der Hagen M; Lütschg J; Schmoor C; Ihorst G; Korinthenberg R
Lancet Neurol; 2010 Nov; 9(11):1053-9. PubMed ID: 20801085
[TBL] [Abstract][Full Text] [Related]
22. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.
Biggar WD; Harris VA; Eliasoph L; Alman B
Neuromuscul Disord; 2006 Apr; 16(4):249-55. PubMed ID: 16545568
[TBL] [Abstract][Full Text] [Related]
23. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy.
Connolly AM; Schierbecker J; Renna R; Florence J
Neuromuscul Disord; 2002 Dec; 12(10):917-25. PubMed ID: 12467746
[TBL] [Abstract][Full Text] [Related]
24. Vibration therapy tolerated in children with Duchenne muscular dystrophy: a pilot study.
Myers KA; Ramage B; Khan A; Mah JK
Pediatr Neurol; 2014 Jul; 51(1):126-9. PubMed ID: 24830767
[TBL] [Abstract][Full Text] [Related]
25. A survey of the feasibility of developing osteoporosis clinical trials in Duchenne muscular dystrophy: Survey of the opinion of young people with Duchenne muscular dystrophy, families and clinicians.
Choong Wong S; Joseph S; Capaldi N; Marco MD; Dunne J; Guglieri M; Horrocks I; Straub V; Faisal Ahmed S;
Clin Trials; 2021 Feb; 18(1):39-50. PubMed ID: 33012180
[TBL] [Abstract][Full Text] [Related]
26. Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up.
Lebel DE; Corston JA; McAdam LC; Biggar WD; Alman BA
J Bone Joint Surg Am; 2013 Jun; 95(12):1057-61. PubMed ID: 23783200
[TBL] [Abstract][Full Text] [Related]
27. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
Wong BL; Christopher C
J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
[TBL] [Abstract][Full Text] [Related]
28. Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy.
Tandon A; Villa CR; Hor KN; Jefferies JL; Gao Z; Towbin JA; Wong BL; Mazur W; Fleck RJ; Sticka JJ; Benson DW; Taylor MD
J Am Heart Assoc; 2015 Mar; 4(4):. PubMed ID: 25814625
[TBL] [Abstract][Full Text] [Related]
29. Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism.
Al-Khalidi R; Panicucci C; Cox P; Chira N; Róg J; Young CNJ; McGeehan RE; Ambati K; Ambati J; Zabłocki K; Gazzerro E; Arkle S; Bruno C; Górecki DC
Acta Neuropathol Commun; 2018 Apr; 6(1):27. PubMed ID: 29642926
[TBL] [Abstract][Full Text] [Related]
30. Steroids in Duchenne muscular dystrophy--deflazacort trial.
Mesa LE; Dubrovsky AL; Corderi J; Marco P; Flores D
Neuromuscul Disord; 1991; 1(4):261-6. PubMed ID: 1822804
[TBL] [Abstract][Full Text] [Related]
31. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.
Ma J; McMillan HJ; Karagüzel G; Goodin C; Wasson J; Matzinger MA; DesClouds P; Cram D; Page M; Konji VN; Lentle B; Ward LM
Osteoporos Int; 2017 Feb; 28(2):597-608. PubMed ID: 27774565
[TBL] [Abstract][Full Text] [Related]
32. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
[TBL] [Abstract][Full Text] [Related]
33. Rehabilitation interventions for foot drop in neuromuscular disease.
Sackley C; Disler PB; Turner-Stokes L; Wade DT; Brittle N; Hoppitt T
Cochrane Database Syst Rev; 2009 Jul; (3):CD003908. PubMed ID: 19588347
[TBL] [Abstract][Full Text] [Related]
34. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up.
Houde S; Filiatrault M; Fournier A; Dubé J; D'Arcy S; Bérubé D; Brousseau Y; Lapierre G; Vanasse M
Pediatr Neurol; 2008 Mar; 38(3):200-6. PubMed ID: 18279756
[TBL] [Abstract][Full Text] [Related]
35. Steroid Responsiveness in Duchenne Muscular Dystrophy - Predictive Value of Epigenetic Regulator Histone Deacetylase 2.
Pradhan S; Das A; Singh H; Chaturvedi S; Singh K; Mishra R; Misra DP; Agarwal V
Indian J Pediatr; 2020 Sep; 87(9):692-698. PubMed ID: 32314166
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcomes of steroid therapy for Duchenne muscular dystrophy in Japan.
Goto M; Komaki H; Takeshita E; Abe Y; Ishiyama A; Sugai K; Sasaki M; Goto Y; Nonaka I
Brain Dev; 2016 Oct; 38(9):785-91. PubMed ID: 27112384
[TBL] [Abstract][Full Text] [Related]
37. Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort.
Singh A; Schaeffer EK; Reilly CW
J Pediatr Orthop; 2018 Jul; 38(6):320-324. PubMed ID: 27328118
[TBL] [Abstract][Full Text] [Related]
38. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy.
Kinali M; Mercuri E; Main M; Muntoni F; Dubowitz V
Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S169-74. PubMed ID: 12206813
[TBL] [Abstract][Full Text] [Related]
39. Liposomal steroid nano-drug is superior to steroids as-is in mdx mouse model of Duchenne muscular dystrophy.
Turjeman K; Yanay N; Elbaz M; Bavli Y; Gross M; Rabie M; Barenholz Y; Nevo Y
Nanomedicine; 2019 Feb; 16():34-44. PubMed ID: 30529791
[TBL] [Abstract][Full Text] [Related]
40. The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials.
Alfano LN; Miller NF; Berry KM; Yin H; Rolf KE; Flanigan KM; Mendell JR; Lowes LP
Neuromuscul Disord; 2017 May; 27(5):452-457. PubMed ID: 28279570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
